Your browser doesn't support javascript.
loading
Delayed Recognition of Levetiracetam-induced Pancytopenia.
Ammad Ud Din, Mohammad; Ather Hussain, Syed; Bodrog, Amy.
Afiliação
  • Ammad Ud Din M; Internal Medicine, Rochester General Hospital, Rochester, New York, USA.
  • Ather Hussain S; Internal Medicine, Rochester General Hospital, Rochester, New York, USA.
  • Bodrog A; Hematology/Oncology, Rochester General Hospital, Rochester, New York, USA.
Eur J Case Rep Intern Med ; 8(3): 002449, 2021.
Article em En | MEDLINE | ID: mdl-33869106
ABSTRACT
Blood dyscrasias associated with levetiracetam use can be difficult to identify, especially when other potential differential diagnoses are concurrently present. Here we present a 57-year-old man with metastatic adenocarcinoma of unknown primary origin on levetiracetam who initially presented with an in-stent thrombosis of the right external iliac vein and then developed worsening thrombocytopenia followed by pancytopenia. Levetiracetam was not identified as the culprit until other causes like platelet consumption, heparin-induced thrombocytopenia, idiopathic immune thrombocytopenic purpura, and bone marrow involvement by metastatic disease were ruled out. LEARNING POINTS Levetiracetam can cause both acute and delayed-onset pancytopenia through bone marrow suppression.The phenomenon is normally reversible and blood counts improve with drug cessation.Clinicians should consider checking a complete blood profile within a month of drug initiation, particularly in high-risk patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article